Retinal indoleamine accumulating neurons.

Neurochem Int

Dept. of Ophthalmology, Univ. of Lund, S-221 85 Lund, Sweden.

Published: October 2012

A previously unknown set of neurons, characterized by their ability to accumulate indoleamines, has been identified in the retina of Cebus monkeys, rabbits, cats, pigeons, chicken, goldfish and lampreys. They are not demonstrable with presently available techniques in humans, Cynomolgus monkeys, cows, pigs and rats. The neurons are called indoleamine accumulating neuron and form a subset of amacrine cells, distinguishable from all other subsets of amacrines with known transmitter. By electron microscopy they have been shown to be contacted by bipolar cells in the dyad arrangement and to form reciprocal contacts on the bipolar cells. A procedure is available for destroying selectively the processes of the indoleamine accumulating neurons. The indoleamine accumulating neurons do not show any formaldehyde induced fluorescence in the normal animals or in animals in which the 5-hydroxytryptamine concentration in the brain has been elevated pharmacologically, and the 5-hydroxytryptamine concentration in the normal retina is too low to make it a likely neurotransmitter. What little is present is presumably in blood platelets in most cases (chicken may be an exception). The rate limiting enzyme in the 5-hydroxytryptamine synthesis, tryptophan hydroxylase, is not detectable in the retina. 5-hydroxytryptamine does not elicit any increase in retinal cyclic AMP. There is an energy dependent, high affinity uptake system for indoleamines but the effect of various inhibitors is different from that on the uptake into brain tissue. Several lines of evidence thus disfavour 5-hydroxytryptamine as a retinal neurotransmitter. Nevertheless, the active uptake of indoleamines suggests that the transmitter of the indoleamine accumulating neurons is an indole which, however, at present remains unidentified.

Download full-text PDF

Source
http://dx.doi.org/10.1016/0197-0186(80)90062-5DOI Listing

Publication Analysis

Top Keywords

indoleamine accumulating
20
accumulating neurons
16
bipolar cells
8
5-hydroxytryptamine concentration
8
neurons
6
accumulating
5
5-hydroxytryptamine
5
retinal indoleamine
4
neurons unknown
4
unknown set
4

Similar Publications

Engineering bacteria for cancer immunotherapy by inhibiting IDO activity and reprogramming CD8+ T cell response.

Proc Natl Acad Sci U S A

December 2024

Laboratory for Biomaterial and Immunoengineering, Institute of Functional Nano and Soft Materials, Soochow University, Suzhou, Jiangsu 215123, China.

Inhibiting indoleamine 2,3 dioxygenase (IDO) for anticancer therapy has garnered significant attention in recent years. However, current IDO inhibitors face significant challenges which limit their clinical application. Here, we genetically engineered a high tryptophan-expressing (L-Trp CB) strain that can colonize tumors strictly following systemic administration.

View Article and Find Full Text PDF

The clinical efficacy of immune checkpoint blockade (ICB) therapy is significantly compromised in the metabolically disordered tumor microenvironment (TME), posing a formidable challenge that cannot be ignored in current antitumor strategies. In this study, TME-responsive nanoparticles (HMP1G NPs) loaded with 1-methyltryptophan (1-MT; an indoleamine 2,3-dioxygenase 1 [IDO1] inhibitor,) and S-nitrosoglutathione (GSNO; a nitric oxide donor) is developed to enhance the therapeutic efficacy of 1-MT-mediated ICB. The HMP1G NPs responded to H and glutathione in the TME, releasing Mn, GSNO, and 1-MT.

View Article and Find Full Text PDF

IDO1-mediated catabolism of tryptophan in gastric tumors: Its potential role in the axis of histopathology, differentiation and metastasis.

Pathol Res Pract

November 2024

Department of Molecular Medicine, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey. Electronic address:

Background: Indoleamine 2,3-Dioxygenase 1 (IDO1)-mediated tryptophan degradation, which is the rate-limiting enzyme of tryptophan/kynurenine pathway, may cause immune suppression in the tumor microenvironment, while potentiating proliferative and metastatic activity in the tumor focus, Phase studies of IDO1 inhibitors are ongoing, and our study aims to evaluate the potential contribution of IDO1 gene expression to the tryptophan/kynurenine pathway in tumor and tumor microenvironment foci in gastric cancer (GC) on a clinicopathological axis, METHOD: In the case-control study design, the determination of tryptophan and its metabolites in the serum of 51 GC and 49 healthy controls was made using High Pressure Liquid Chromatography-Fluorescence Detector (HPLC-FD). IDO1 expression in a total of 102 tissues with tumor and tumor microenvironment was detected by quantitative PCR (q-PCR).

Results: In gastric tumors, 3,25-fold decreased expression of IDO1 was detected according to the tumor microenvironment (p=0,05), IDO1 expression was found to be more than 2 times higher in signet ring cell carcinoma (SRCC) and poorly differentiated tumors without distant organ metastasis (p<0,05), In GC, tryptophan level was found to be 1,6 times lower than in control (AUC:0889; cut off≤21,57; p<0001), Low tryptophan level was found in advanced tumor stage compared to early stage and in the presence of perineural invasion compared to its absence (p<0,05) The level of kynurenine was found to be approximately 1,8 times lower in SRCC (p=0,04), CONCLUSION: Increased tryptophan accumulation in the gastric tumor and its microenvironment, when catabolized via IDO1, exhibits histological type, tumor differentiation, and metastasis-promoting effects more prominently in aggressive subtypes such as SRCC.

View Article and Find Full Text PDF

Tryptophan Metabolism in Obesity: The Indoleamine 2,3-Dioxygenase-1 Activity and Therapeutic Options.

Adv Exp Med Biol

September 2024

Faculty of Medicine, Department of General Surgery, Gazi University, Besevler, Ankara, Turkey.

Obesity activates both innate and adaptive immune responses in adipose tissue. Adipose tissue macrophages are functional antigen-presenting cells that promote the proliferation of interferon-gamma (IFN-γ)-producing cluster of differentiation (CD)4+ T cells in adipose tissue of obese subjects. The increased formation of neopterin and degradation of tryptophan may result in decreased T-cell responsiveness and lead to immunodeficiency.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!